SAB Biotherapeutics (SABS) Invested Capital (2021 - 2023)

SAB Biotherapeutics' Invested Capital history runs 3 years deep, the most recent figure standing at $3.6 million for Q2 2023.

• Quarterly Invested Capital changed N/A year-over-year to $3.6 million in Q2 2023, while the trailing twelve-month figure through Mar 2024 was $3.6 million (down 51.77% YoY) and the FY2022 annual result came in at $3.8 million, down 4.1% from the prior year.
• Invested Capital was $3.6 million for Q2 2023 at SAB Biotherapeutics, down from $3.7 million in the prior quarter.
• Across five years, Invested Capital topped out at $3.9 million in Q4 2021 and bottomed at $3.6 million in Q2 2023.
• A 3-year average of $3.8 million and a median of $3.7 million in 2022 frame the typical range for Invested Capital.
• Peak annual rise in Invested Capital reached 4.1% in 2022, while the deepest fall reached 4.1% in 2022.
• SAB Biotherapeutics' Invested Capital stood at $3.9 million in 2021, then declined by 4.1% to $3.8 million in 2022, then fell by 3.98% to $3.6 million in 2023.
• Business Quant data shows SABS's Invested Capital at $3.6 million in Q2 2023, $3.7 million in Q1 2023, and $3.8 million in Q4 2022.